期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

ACEI/ARB联合氢氯噻嗪治疗IgA肾病的疗效观察

下载PDF
导出
摘要 目的:探讨血管紧张素转化酶抑制剂或血管紧张素受体阻滞剂(ACEI/ARB)联合氢氯噻嗪在治疗Ig A肾病中的疗效.方法:将36例蛋白尿>0.5/g的原发性Ig A肾病患者随机均分成两组.对照组采用常规ACEI/ARB进行治疗,实验组在原有ACEI/ARB治疗的基础上加用氢氯噻氢治疗.观察两组患者治疗过程中第1周、4周、8周、12周尿蛋白含量变化.结果:治疗后对照组患者尿蛋白含量显著下降者3例,占对照组患者的16.7%;实验组患者尿蛋白显著下降者7例,占实验组患者的38.9%,两组疗效比较差异有统计学意义(P<0.05),结论:ACEI/ARB联合氢氯噻嗪可显著降低Ig A肾病患者尿蛋白含量,对治疗Ig A肾病有效.
作者 马飞 赵海玉
机构地区 赤峰市医院 赤峰学院附属医院
出处 《赤峰学院学报（自然科学版）》 2015年第23期84-85,共2页 Journal of Chifeng University(Natural Science Edition)
关键词 IGA肾病 蛋白尿 氢氯噻嗪
分类号 R692.3 [医药卫生—泌尿科学]
  • 相关文献

参考文献9

  • 1Lv j Zhang H Zhou Y et al.Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China. Nephrology (Carlton), 2008,13(3): 242-246.
  • 2Tran M M. Childhood IgA-mediated epider- molysis bullosa acquisita responding to my- cophenolate mofetil as a corticosteroid-sparing agent. J Am Acad Dermatol,2006,54 (4): 734- 736.
  • 3D'Amico GNatural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol,2004,24(3): 179-196.
  • 4Reich H N Troyanov S Scholey J Wet al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol,2007,18 (12) :3177-3183.
  • 5Ambrosioni E C Borghi B Magnani.The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med, 1995, 332(2): 80-85.
  • 6Ma Y C Zuo L Chen J H et al.Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol,2006,17(10): 2937-2944.
  • 7Coppo R Peruzzi LAmore A et al.IgACE: a placebo-controlled, randomized trial of an- giotensin-converting enzyme inhibitors in chil- dren and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol, 2007.18(6: 1880-1888.
  • 8宋海宁,赖海燕,李茜.依那普利或厄贝沙坦联合氢氯噻嗪治疗中重度高血压的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(16):1563-1565. 被引量：31
  • 9万青松,谢红萍,杨波.安体舒通联合氢氯噻嗪对2型糖尿病肾病蛋白尿的影响[J].中国现代医学杂志,2015,25(5):57-60. 被引量：11

二级参考文献19

  • 1郭旭梅 ,武一平 ,毕隽芳 ,李杰 .氯沙坦与依那普利治疗高血压合并高尿酸血症各34例的比较[J].中国新药与临床杂志,2004,23(8):540-542. 被引量：12
  • 2郝柏杨,柴栋木,卢艳玲,等.原发性高血压的诊断[J].中外健康文摘,2012,33(1):52.
  • 3HOVIND P, ROSSING P, TARNNOW L, et al. Progression of diabetic nephropathy[J]. Kidney Int, 2001, 59: 702-709.
  • 4BILOUS R, CHATURVEDI N, SJELIE AK, et al. Effect of can- desartan on microalbuminuria and albumin excretion rate in dia- betes: three randomized trials[J]. Ann Intern Med, 2009, 151(1): 11-20.
  • 5BOZKURT B, AGOSTON I, KNOWLTON AA. Complication of inappropriate use of spironolactone in heart failure: When an old medicine spirals out of new guidelines[J]. J Am Coll Cardiol, 2003, 41: 211-214.
  • 6SCHJOEDT KJ, ROSSING K, JUHL TR, et al. Beneficial impact of spironolactone in diabetic nephropathy[J]. Kidney Int, 2005, 68 (6): 2829-2836.
  • 7BIANCHI S, BIGAZZI R, CAMPESE VM. Antagonists of aldos- terone and proteinuria in patients with CKD: an uncontrolled pi- lot study[J]. Am J Kidney Dis, 2005, 46(1): 45-51.
  • 8CHRYSOSTOMOU A, BECKER G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic re- nal disease[J]. N Engl J Med, 2001, 345(12): 925-926.
  • 9SATO A, HAYASHI K, NARUSE M, et al. Effectiveness of al- dosterone blockade in patients with diabetic nephropathy[J]. Hy- pertention, 2003, 41(1): 64-68.
  • 10GUNEY I, SELCUK NY, ALTINTEPE L, et al. Antifibrotic ef- fects of aldosterone receptor blocker (spiranolactone) in patients with chronic kidney disease[J]. Ren Fail, 2009, 31(9): 779-784.

共引文献40

赤峰学院学报（自然科学版）
2015年 第23期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部